Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

OncoGenex Pharmaceuticals, Inc. (OGXI - Snapshot Report) recently announced the commencement of an investigator-sponsored phase II trial, Rainer, on its oncology candidate, apatorsen.

We note that OncoGenex is evaluating apatorsen (OGX-427) in combination with Celgene Corporation’s (CELG - Analyst Report) Abraxane and Gemzar in patients with previously untreated metastatic pancreatic cancer.

The randomized, placebo-controlled study will randomize 130 patients to receive either apatorsen or placebo in combination with Abraxane and Gemzar therapy. The primary end point is overall survival.

Other end points include progression-free survival (PFS), tumor response rates, safety, and tolerability among others.

OncoGenex estimates approximately 45,000 people will be diagnosed with pancreatic cancer in the U.S. leading to approximately 38,500 deaths in 2013. Hence, a positive result from the trial will be a significant step forward for OncoGenex to come up with a potential treatment option for pancreatic cancer.

Earlier in the month, OncoGenex initiated another phase II trial, Spruce, on apatorsen. OncoGenex is evaluating apatorsen for the treatment of previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).

The trials are part of the ORCA (Ongoing Studies Evaluating Treatment Resistance in CAncer) program.

We remind investors that the most advanced candidate in OncoGenex’s pipeline is custirsen (phase III) under evaluation for the treatment of metastatic castrate-resistant prostate cancer in men and also for the treatment of patients with advanced, unresectable non-small cell lung cancer.

OncoGenex has a global collaboration and license agreement with Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report) to develop and commercialize the candidate.

The successful development and commercialization of custirsen will be a major positive for OncoGenex. OncoGenex currently has no approved drug in its portfolio. We expect investor focus to remain on custirsen.

OncoGenex currently carries a Zacks Rank #3 (Hold). Right now, Jazz Pharmaceuticals (JAZZ - Analyst Report) looks attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%